



Date: May 16, 2024

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (East) <u>Mumbai – 400 051</u> Stock Code : INDOCO-EQ	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, <u>Mumbai – 400 001</u> Stock Code : 532612
---	---

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 –Completion of Inspection at Indoco Remedies Limited API Kilo Lab Manufacturing Facility and Indoco Analytical Solutions Division

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that United States Food and Drug Administration (USFDA) had inspected Company's API Kilo Lab Manufacturing facility (Kilo Lab) located at Rabale, Navi Mumbai ("Facility") and Indoco Analytical Solutions (IAS) Division.

The inspection was concluded with zero Form 483 observations.

Please find enclosed herewith press release in this regard. Kindly take the above information on record.

Thanking you,
Yours faithfully,
For Indoco Remedies Limited



Ramanathan Hariharan
Company Secretary & Head- Legal



PRESS RELEASE

USFDA successfully completes inspection at Indoco's API Kilo Lab manufacturing facility and IAS division without any observations

May 16, 2024, Mumbai: Indoco Remedies Limited announced today that, the United States Food and Drug Administration (USFDA) successfully completed inspection of its API Kilo Lab manufacturing facility at Rabale, Navi Mumbai and Indoco Analytical Solutions (IAS) division. The inspection concluded with zero Form 483 observations, reflecting the company's commitment to maintaining the highest standards of quality and compliance.

"We are extremely happy with the outcome of this inspection. This achievement reflects our relentless focus on quality and compliance in everything we do. We remain committed to ensuring the safety and efficacy of our products while maintaining the trust of our customers and stakeholders", said Ms. Aditi Panandikar, Managing Director, Indoco Remedies Limited.

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 212 million with a human capital of over 6000 employees, including over 400 skilled scientists and Field Staff who are the strength of the organization.

The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,35,000 doctors belonging to various specialties. Indoco has 8 domestic marketing divisions a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritional, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensiform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexidin,

MCBM 69, Methycal, Dropizine, Noxa, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Pramod Ghorpade | Mobile: 9619883225

E-mail: pramod.ghorpade@indoco.com / corpcom@indoco.com